Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

3.060 -0.070 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mind Medicine Mindmed Inc

< Previous 1 2 3 Next >
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Mind Science Targeting Big Brains and Portfolios
Via AB Newswire
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
MindMed to Participate at September Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
From Mind Medicine (MindMed) Inc
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces Election of All Six Company Nominees at Annual Meeting
From Mind Medicine
Via Business Wire
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
From Mind Medicine
Via Business Wire
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Adjourns Annual General Meeting of Shareholders
From Mind Medicine
Via Business Wire
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
From MindMed
Via Business Wire
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
From Mind Medicine (MindMed) Inc.
Via Business Wire
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed to Host Investor Day June 2023
From Mind Medicine
Via Business Wire
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
From MindMed
Via Business Wire
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed to Participate at Upcoming Investor Conferences
From Mind Medicine
Via Business Wire
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
From MindMed
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.